The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

Stifel Initiates Summit Therapeutics With Buy Rating and $45 Price Target

Key Facts

1Stifel initiated coverage on Summit Therapeutics with a Buy rating and a price target of $45.00.

2The price target represents a potential upside of 134% based on the potential of the drug Ivonescimab.

Investment bank Stifel has initiated coverage on Summit Therapeutics (SMMT) with a Buy rating and a price target of $45.00. This target suggests a significant potential upside of 134%, primarily driven by the clinical prospects of the company's lead drug, Ivonescimab. Analysts highlighted the strong potential of this bispecific antibody within large-scale markets, despite recent earnings misses. While there are some uncertainties regarding the timing of clinical trials in China, the overall outlook remains highly bullish. This initiation by a reputable firm is expected to drive positive investor sentiment and buying pressure for the biotech stock. The market is now closely watching the progress of Ivonescimab as a key catalyst for the company's valuation.